197 results on '"Dreaden, Erik C."'
Search Results
2. Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML
3. Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia
4. B-cell acute lymphoblastic leukemia promotes an immune suppressive microenvironment that can be overcome by IL-12
5. Engineering Improved CAR T Cell Products with A Multi‐Cytokine Particle Platform for Hematologic and Solid Tumors
6. The T-cell niche tunes immune function through modulation of the cytoskeleton and TCR-antigen forces
7. Detecting and Destroying Cancer Cells in More Than One Way with Noble Metals and Different Confinement Properties on the Nanoscale *
8. Exploiting Nanocarriers for Combination Cancer Therapy
9. Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints
10. Engineering nanolayered particles for modular drug delivery
11. Supplementary Figures S1 - S2 from Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle
12. Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML
13. Multicolor Light-Induced Immune Activation via Polymer Photocaged Cytokines
14. Adsorption of hyaluronic acid on solid supports: Role of pH and surface chemistry in thin film self-assembly
15. Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia
16. Multicolor Light-Induced Immune Activation via Polymer Photocaged Cytokines
17. Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic Leukemia
18. PEG: Will It Come Back to You? Polyethelyne Glycol Immunogenicity, COVID Vaccines, and the Case for New PEG Derivatives and Alternatives
19. Abstract 3339: MRX-2843, a dual MERTK and FLT3 inhibitor, mediates synergistic anti-leukemia activity in combination with BCL-2 inhibitors in acute myeloid leukemia and early T-cell precursor acute lymphoblastic leukemia
20. PEG: Will It Come Back to You? Polyethelyne Glycol Immunogenicity, COVID Vaccines, and the Case for New PEG Derivatives and Alternatives
21. Exploiting Nanocarriers for Combination Cancer Therapy
22. The optical, photothermal, and facile surface chemical properties of gold and silver nanoparticles in biodiagnostics, therapy, and drug delivery
23. Engineering Layer-by-Layer Thin Films for Multiscale and Multidrug Delivery Applications
24. Structure–Activity Relationships for Tumor-Targeting Gold Nanoparticles
25. Rational design of multistage drug delivery vehicles for pulmonary RNA interference therapy
26. Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints
27. Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice
28. Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy
29. Size matters: gold nanoparticles in targeted cancer drug delivery
30. Rational design of multistage drug delivery vehicles for pulmonary RNA interference therapy
31. Rapid Assembly and Screening of Multivalent Immune Cell-Redirecting Therapies for Leukemia
32. Optical Control of Cytokine Signaling via Bioinspired, Polymer-Induced Latency
33. Promoting anti-tumor immunity via bispecific T cell engaging cytokine (biteokine) therapy
34. Chemical modification strategies for photo-induced control of immune cell signaling
35. Photo-regulated control of cytokine signaling via bioinspired, polymer-induced latency
36. Optical Control of Cytokine Signaling via Bioinspired, Polymer-Induced Latency
37. Tuning Nanoparticle Interactions with Ovarian Cancer through Layer-by-Layer Modification of Surface Chemistry
38. RNA‐Peptide nanoplexes drug DNA damage pathways in high‐grade serous ovarian tumors
39. Nanoparticle Surface Functionality Dictates Cellular and Systemic Toxicity
40. Nanoparticle Surface Functionality Dictates Cellular and Systemic Toxicity
41. Cellular uptake of nanoparticles: journey inside the cell
42. Nanoparticle Surface Functionality Dictates Cellular and Systemic Toxicity
43. Layer-by-Layer Nanoparticles for Systemic Codelivery of an Anticancer Drug and siRNA for Potential Triple-Negative Breast Cancer Treatment
44. Designer Dual Therapy Nanolayered Implant Coatings Eradicate Biofilms and Accelerate Bone Tissue Repair
45. Innenrücktitelbild: A Multi‐RNAi Microsponge Platform for Simultaneous Controlled Delivery of Multiple Small Interfering RNAs (Angew. Chem. 10/2016)
46. Inside Back Cover: A Multi-RNAi Microsponge Platform for Simultaneous Controlled Delivery of Multiple Small Interfering RNAs (Angew. Chem. Int. Ed. 10/2016)
47. Nanostructures: Highly Scalable, Closed-Loop Synthesis of Drug-Loaded, Layer-by-Layer Nanoparticles (Adv. Funct. Mater. 7/2016)
48. Highly Scalable, Closed-Loop Synthesis of Drug-Loaded, Layer-by-Layer Nanoparticles
49. Periodic-shRNA molecules are capable of gene silencing, cytotoxicity and innate immune activation in cancer cells
50. A Multi-RNAi Microsponge Platform for Simultaneous Controlled Delivery of Multiple Small Interfering RNAs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.